289 related articles for article (PubMed ID: 24986746)
1. 3-Dimensional magnetic resonance spectroscopic imaging at 3 Tesla for early response assessment of glioblastoma patients during external beam radiation therapy.
Muruganandham M; Clerkin PP; Smith BJ; Anderson CM; Morris A; Capizzano AA; Magnotta V; McGuire SM; Smith MC; Bayouth JE; Buatti JM
Int J Radiat Oncol Biol Phys; 2014 Sep; 90(1):181-9. PubMed ID: 24986746
[TBL] [Abstract][Full Text] [Related]
2. Magnetic resonance spectroscopy as an early indicator of response to anti-angiogenic therapy in patients with recurrent glioblastoma: RTOG 0625/ACRIN 6677.
Ratai EM; Zhang Z; Snyder BS; Boxerman JL; Safriel Y; McKinstry RC; Bokstein F; Gilbert MR; Sorensen AG; Barboriak DP
Neuro Oncol; 2013 Jul; 15(7):936-44. PubMed ID: 23645534
[TBL] [Abstract][Full Text] [Related]
3. [Application of (1)H MR spectroscopic imaging in radiation oncology: choline as a marker for determining the relative probability of tumor progression after radiation of glial brain tumors].
Lichy MP; Bachert P; Hamprecht F; Weber MA; Debus J; Schulz-Ertner D; Schlemmer HP; Kauczor HU
Rofo; 2006 Jun; 178(6):627-33. PubMed ID: 16703499
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the lactate-to-N-acetyl-aspartate ratio defined with magnetic resonance spectroscopic imaging before radiation therapy as a new predictive marker of the site of relapse in patients with glioblastoma multiforme.
Deviers A; Ken S; Filleron T; Rowland B; Laruelo A; Catalaa I; Lubrano V; Celsis P; Berry I; Mogicato G; Cohen-Jonathan Moyal E; Laprie A
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):385-93. PubMed ID: 25104068
[TBL] [Abstract][Full Text] [Related]
5. Serial analysis of 3D H-1 MRSI for patients with newly diagnosed GBM treated with combination therapy that includes bevacizumab.
Nelson SJ; Li Y; Lupo JM; Olson M; Crane JC; Molinaro A; Roy R; Clarke J; Butowski N; Prados M; Cha S; Chang SM
J Neurooncol; 2016 Oct; 130(1):171-179. PubMed ID: 27535746
[TBL] [Abstract][Full Text] [Related]
6. Volumetric spectroscopic imaging of glioblastoma multiforme radiation treatment volumes.
Parra NA; Maudsley AA; Gupta RK; Ishkanian F; Huang K; Walker GR; Padgett K; Roy B; Panoff J; Markoe A; Stoyanova R
Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):376-84. PubMed ID: 25066215
[TBL] [Abstract][Full Text] [Related]
7. Proton magnetic resonance spectroscopic imaging in newly diagnosed glioblastoma: predictive value for the site of postradiotherapy relapse in a prospective longitudinal study.
Laprie A; Catalaa I; Cassol E; McKnight TR; Berchery D; Marre D; Bachaud JM; Berry I; Moyal EC
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):773-81. PubMed ID: 18262090
[TBL] [Abstract][Full Text] [Related]
8. Predicting the outcome of grade II glioma treated with temozolomide using proton magnetic resonance spectroscopy.
Guillevin R; Menuel C; Taillibert S; Capelle L; Costalat R; Abud L; Habas C; De Marco G; Hoang-Xuan K; Chiras J; Vallée JN
Br J Cancer; 2011 Jun; 104(12):1854-61. PubMed ID: 21610707
[TBL] [Abstract][Full Text] [Related]
9. Longitudinal multivoxel MR spectroscopy study of pediatric diffuse brainstem gliomas treated with radiotherapy.
Laprie A; Pirzkall A; Haas-Kogan DA; Cha S; Banerjee A; Le TP; Lu Y; Nelson S; McKnight TR
Int J Radiat Oncol Biol Phys; 2005 May; 62(1):20-31. PubMed ID: 15850898
[TBL] [Abstract][Full Text] [Related]
10. Quantification of serial changes in cerebral blood volume and metabolism in patients with recurrent glioblastoma undergoing antiangiogenic therapy.
Stadlbauer A; Pichler P; Karl M; Brandner S; Lerch C; Renner B; Heinz G
Eur J Radiol; 2015 Jun; 84(6):1128-36. PubMed ID: 25795194
[TBL] [Abstract][Full Text] [Related]
11. MR spectroscopy using normalized and non-normalized metabolite ratios for differentiating recurrent brain tumor from radiation injury.
Elias AE; Carlos RC; Smith EA; Frechtling D; George B; Maly P; Sundgren PC
Acad Radiol; 2011 Sep; 18(9):1101-8. PubMed ID: 21820634
[TBL] [Abstract][Full Text] [Related]
12. Patterns of recurrence analysis in newly diagnosed glioblastoma multiforme after three-dimensional conformal radiation therapy with respect to pre-radiation therapy magnetic resonance spectroscopic findings.
Park I; Tamai G; Lee MC; Chuang CF; Chang SM; Berger MS; Nelson SJ; Pirzkall A
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):381-9. PubMed ID: 17513061
[TBL] [Abstract][Full Text] [Related]
13. Patterns of failure and comparison of different target volume delineations in patients with glioblastoma treated with conformal radiotherapy plus concomitant and adjuvant temozolomide.
Minniti G; Amelio D; Amichetti M; Salvati M; Muni R; Bozzao A; Lanzetta G; Scarpino S; Arcella A; Enrici RM
Radiother Oncol; 2010 Dec; 97(3):377-81. PubMed ID: 20855119
[TBL] [Abstract][Full Text] [Related]
14. Association of early changes in 1H MRSI parameters with survival for patients with newly diagnosed glioblastoma receiving a multimodality treatment regimen.
Nelson SJ; Kadambi AK; Park I; Li Y; Crane J; Olson M; Molinaro A; Roy R; Butowski N; Cha S; Chang S
Neuro Oncol; 2017 Mar; 19(3):430-439. PubMed ID: 27576874
[TBL] [Abstract][Full Text] [Related]
15. Proton magnetic resonance spectroscopy in immunocompetent patients with primary central nervous system lymphoma.
Raizer JJ; Koutcher JA; Abrey LE; Panageas KS; DeAngelis LM; Lis E; Xu S; Zakian KL
J Neurooncol; 2005 Jan; 71(2):173-80. PubMed ID: 15690135
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma treated with concurrent radiation therapy and temozolomide chemotherapy: differentiation of true progression from pseudoprogression with quantitative dynamic contrast-enhanced MR imaging.
Yun TJ; Park CK; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Choi SH
Radiology; 2015 Mar; 274(3):830-40. PubMed ID: 25333475
[TBL] [Abstract][Full Text] [Related]
17. Applying a Radiation Therapy Volume Analysis Pipeline to Determine the Utility of Spectroscopic MRI-Guided Adaptive Radiation Therapy for Glioblastoma.
Trivedi AG; Kim SH; Ramesh KK; Giuffrida AS; Weinberg BD; Mellon EA; Kleinberg LR; Barker PB; Han H; Shu HG; Shim H; Schreibmann E
Tomography; 2023 May; 9(3):1052-1061. PubMed ID: 37218946
[TBL] [Abstract][Full Text] [Related]
18. Developing a clinical decision model: MR spectroscopy to differentiate between recurrent tumor and radiation change in patients with new contrast-enhancing lesions.
Smith EA; Carlos RC; Junck LR; Tsien CI; Elias A; Sundgren PC
AJR Am J Roentgenol; 2009 Feb; 192(2):W45-52. PubMed ID: 19155380
[TBL] [Abstract][Full Text] [Related]
19. Multiparametric MR Imaging of Diffusion and Perfusion in Contrast-enhancing and Nonenhancing Components in Patients with Glioblastoma.
Boonzaier NR; Larkin TJ; Matys T; van der Hoorn A; Yan JL; Price SJ
Radiology; 2017 Jul; 284(1):180-190. PubMed ID: 28240563
[TBL] [Abstract][Full Text] [Related]
20. In vivo differentiation of aerobic brain abscesses and necrotic glioblastomas multiforme using proton MR spectroscopic imaging.
Lai PH; Weng HH; Chen CY; Hsu SS; Ding S; Ko CW; Fu JH; Liang HL; Chen KH
AJNR Am J Neuroradiol; 2008 Sep; 29(8):1511-8. PubMed ID: 18499784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
